SLC44A2 and colorectal carcinoma: To further investigate whether SLC44A2 downregulates CPT2 expression by decreasing its acetylation, we treated SLC44A2-overexpressing CRC cells with 3-TYP, a known inhibitor of SIRT3, which is a critical deacetylase of CPT2 [18, 19].